November 22, 2024 – UCB announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).2 BI……
November 27, 2024 – Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Spe……
October 27, 2024 – GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for gepotidacin, an investigational, first-in-class oral antibiotic with a n……
October 22, 2024 – The U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 22 years of ag……
September 24, 2024 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Commission (EC) has granted marketing authorization for Anzupgo® (delgocitinib) cream for the treatment of ad……
September 23, 2024 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for a……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
